Percent ventricular pacing with managed ventricular pacing mode in standard pacemaker population
|
|
- Basil McGee
- 5 years ago
- Views:
Transcription
1 Europace (2008) 10, doi: /europace/eum288 Percent ventricular pacing with managed ventricular pacing mode in standard pacemaker population Goran Milasinovic 1 *, Karlheinz Tscheliessnigg 2, Anthonie Boehmer 3, Vladimir Vancura 4, Andreas Schuchert 5, Johan Brandt 6, Christopher Wiggenhorn 7, Maaike Hofman 8, and Johannes Sperzel 9 1 Clinical Center of Serbia, Belgrade, Serbia and Montenegro; 2 Universitäts Klinikum Graz, Graz, Austria; 3 Atrium Medisch Centrum, Heerlen, The Netherlands; 4 Institutu Klinické a Experimentální Medicíny, Prague, Czech Republic; 5 Universitätsklinikum Hamburg, Hamburg, Germany; 6 University Hospital Lund, Lund, Sweden; 7 Medtronic Inc., Minneapolis, MN, USA; 8 Medtronic Bakken Research Center, Maastricht, The Netherlands; and 9 Kerckhoff-Klinik, Bad Nauheim, Germany Received 12 September 2007; accepted after revision 10 December 2007; online publish-ahead-of-print 18 January 2008 KEYWORDS Managed ventricular pacing; Ventricular pacing; Pacing algorithms; Sinus node disease; Atrioventricular block Aims Unnecessary right ventricular pacing has deleterious effects and becomes more significant when cumulative percent ventricular pacing (Cum%VP) exceeds 40% of time. The Managed Ventricular Pacing (MVP) mode has been shown to significantly reduce the percent ventricular pacing compared to the DDD/R mode. This study assessed the percent of ventricular pacing in a standard pacemaker population programmed to MVP and for which patients it is possible to achieve a Cum%VP 40%. Methods and results Unselected, consecutive patients were implanted with a dual chamber pacemaker with a mean follow-up period of 76 days. The Cum%VP was calculated from device diagnostics between pre-hospital discharge (PHD) and the 1-month post implant visit. The median Cum%VP of 107 patients (age years; 53% male) who were programmed to MVP was 3.9%. The median Cum%VP was 1.4% in patients with sinus node disease (SND) and 28.8% in patients with AV block (AVB). Cum%VP 40% was observed in 72% of all patients, in 50% of AVB patients, and in 86% of SND patients. Conclusion The MVP mode is capable of achieving a low percent of ventricular pacing in a standard pacemaker population with SND and AVB. In addition, 72% of patients in MVP mode demonstrated Cum%VP 40%. Introduction Several ICD and pacemaker studies suggest that frequent and unnecessary right ventricular pacing may have adverse long-term effects, including reduced efficacy of myocardial contraction 1,2 and an increased risk of atrial fibrillation and heart failure hospitalization. 3 5 Moreover, the Dual Chamber and VVI Implantable Defibrillator (DAVID) trial showed that ventricular pacing more than 40% of time is associated with a higher risk of hospitalization for heart failure or death. 6 In addition, the Mode Selection Trial (MOST) showed that every 10% increase in cumulative percent ventricular pacing (Cum%VP) (up to 40%), was associated with a 54% relative increase in risk of hospitalization for heart failure, 4 stressing the importance of reducing unnecessary ventricular pacing as much as possible in each patient. * Corresponding author. Tel: þ ; fax: þ address: goran_milas@yahoo.com For this reason, new pacing algorithms have been developed, with the aim of reducing right ventricular pacing. The MVP w algorithm is designed to preserve intrinsic AV conduction and ventricular activation by automatically switching between AAI/R and DDD/R. MVP has been demonstrated to significantly reduce the amount of unnecessary right ventricular pacing in ICD patients 7 and in patients with symptomatic bradycardia. 8 The principal study aim was to determine the burden of ventricular pacing in a standard pacemaker population, programmed to MVP mode. Secondarily, patient groups in which it is possible to achieve a Cum%VP 40% were defined. Methods Study design The Adapta clinical study was a prospective, non-randomized, multicentre clinical study, evaluating the safety and clinical performance of the dual-chamber Adapta w IPG (Model ADDR01, Medtronic). The study was set out to assess the percent of ventricular pacing in Published on behalf of the European Society of Cardiology. All rights reserved. & The Author For permissions please journals.permissions@oxfordjournals.org.
2 152 a standard pacemaker population programmed to MVP and to assess for which patients it is possible to achieve a Cum%VP 40%. The study was conducted in seven European centres. Prior to enrolling any patients, each participating institution obtained local ethics committee approval. All patients gave written informed consent. The study complied with the Declaration of Helsinki. Data were collected during implant, pre-hospital discharge (0 4 days post implant), 1-month post implant (25 45 days post implant), and 3-month post implant ( days post implant), using case report forms and device interrogation save-to-disk files. At these visits, conduction status was evaluated during temporary atrial pacing at 90 bpm. Patient population Patients who had a Class I or II indication for implantation of a dual chamber pacemaker 9 and who were geographically stable and available for follow-up at the study centre were invited to participate in the Adapta clinical study. Patients were excluded from enrolment if they had a mechanical tricuspid valve, a life expectancy less than 2 years, a Class III indication for permanent pacing, lead integrity problems (unless leads were being replaced), were enrolled (or intended to participate) in another clinical trial or met an exclusion criteria required by local law. MVP algorithm The MVP mode provides atrial-based pacing (AAI/R) with ventricular backup. If AV conduction fails for two out of four A A intervals, MVP switches to DDD/R mode. Periodic checks for AV conduction in DDD/ R mode occur. If AV conduction resumes, MVP switches back to AAI/R mode. During atrial tachyarrhythmia, MVP operates in the DDI/R mode. A more detailed explanation of MVP has been published by Sweeney et al. 7 and Gillis et al. 8 Device programming The study was conducted in two phases. Patients enrolled in Phase I (n ¼ 69) were required to have MVP programmed ON immediately after implant. Furthermore, patients with a history of atrial arrhythmias were required to have Atrial Preference Pacing (APP) programmed ON. APP provides consistent atrial pacing at a rate slightly faster than the intrinsic atrial rate. All other device programming was up to the physicians discretion. For patients enrolled in Phase II (n ¼ 54) device programming of all parameters was based on TherapyGuide TM (a patient-condition driven programming algorithm) recommendations, or not if medically justified. Statistical analysis The Adapta clinical study was a prospective, non-randomized, multicentre clinical study. Baseline demographic data are summarized as mean+sd for quantitative variables and as counts (percentages) for categorical data. Medication data were compared among the indication groups using Fisher s exact test. Median Cum%VP is presented as a descriptive statistic for various subgroups of interest. Cum%VP and Cum%AP times were calculated from stored pacemaker diagnostics between PHD and the 1-month post implant visit. For this period of time, Cum%VP is calculated as the number of paced ventricular beats divided by the sum of the number of paced ventricular beats and the number of sensed ventricular beats, expressed as a percentage. Similarly, Cum%AP time is calculated as the number of paced atrial beats divided by the sum of the number of paced atrial beats and the number of sensed atrial beats, expressed as a percentage. SAS Software (Version 9.1) was used to conduct data processing and statistical analysis. Additionally, Excel (Microsoft Office 2003) was used for graphical presentations of results. Results Study population G. Milasinovic et al. Between 30 May 2005 and 22 July 2005, 123 patients were enrolled in the study, of which 120 were implanted with the Adapta IPG. One patient did not meet inclusion criteria; one patient withdrew participation after informed consent form was signed; and a third patient was not yet implanted at the time of enrolment completion. The mean follow-up duration for all 120 implanted patients was 76.3 days with a range of days; the cumulative follow-up was 301 months in all patients. At the time data collection was stopped, several patients did not have their 3-month post implant visit yet. Therefore, we only present data up to the 1-month post implant visit. Of the 120 implanted patients, 107 patients had MVP programmed ON and %VP data available (66 patients in Phase I and 41 patients in Phase II). Of the 68 patients implanted in Phase I, 2 were not programmed to MVP (study deviations). Of the 52 patients implanted in Phase II, 9 were not programmed to MVP [physicians discretion, most likely due to third degree AV block (AVB)], and 2 save-to-disk files were missing. APP was programmed ON in 62% of Phase I patients, and in 30% of Phase II patients. These 107 patients were analysed to (i) assess the percent of ventricular pacing between PHD and the 1-month post implant visit, and (ii) to investigate for which patients it was possible to achieve Cum%VP 40%. Table 1 shows the characteristics for the 107 patients who were eligible for the ventricular pacing analysis between PHD and the 1-month post implant visit. Also medications at baseline are shown. There are no differences in medications among the sinus node disease (SND), AVB, and Other subgroups, except for Calcium channel blockers (SND 27%; AVB 10%; Other 0%, P ¼ ). When compared with the 1-month post implant medication usage, there was a difference in b-blocker use for the total group (18% at baseline, 32% at 1-month, P, 0.05). For 82 patients (out of the 107 eligible patients), an AV conduction test was performed at 90 bpm at the PHD visit. No AV conduction test was performed if the patient had documented third degree AV block (n ¼ 7) or was in atrial fibrillation (n ¼ 8). For 10 patients, the test was not performed for other reasons (study deviations). Percent ventricular pacing with MVP, by primary pacing indication Table 2 shows the median Cum%VP at the 1-month post implant visit for all 107 patients, divided by primary pacing indication. The median Cum%VP for all patients was 3.9%. The median Cum%VP for patients with SND was 1.4% and for AVB patients 28.8%. Figure 1 shows the distribution of Cum%VP and Cum%AP for patients with SND and AVB. Percent ventricular pacing with MVP, in AVB patients The median Cum%VP divided for different types of patients with AVB is shown in Table 3. The median Cum%VP for patients with a medical history of first degree AVB was 8.6%. The median Cum%VP for patients with a medical history of second degree AVB was 6.6%. In addition, the median Cum%VP for patients with a medical history of third degree
3 Percent ventricular pacing with MVP mode 153 Table 1 Characteristics of the study population Primary pacing indication Total (n ¼ 107) AVB (n ¼ 42) SND (n ¼ 59) Other (n ¼ 6) Age (year) Male 57 (53%) 21 (50%) 33 (56%) 3 (50%) NYHA class Class I 17 (16%) 8 (19%) 7 (12%) 2 (33%) Class II 29 (27%) 11 (26%) 16 (27%) 2 (33%) Class III 9 (8%) 3 (7%) 6 (10%) 0 Class IV 1 (1%) 1 (2%) 0 0 Does not meet NYHA 51 (48%) 19 (45%) 30 (51%) 2 (33%) Prior IPG implant 22 (21%) 8 (19%) 12 (20%) 2 (33%) Drugs b-blockers 19 (18%) 5 (12%) 13 (22%) 1 (17%) Digoxin 6 (6%) 0 6 (10%) 0 Class I antiarrhythmics 5 (5%) 0 5 (8%) 0 Class III antiarrhythmics 2 (2%) 0 2 (3%) 0 Calcium channel blockers 20 (19%) 4 (10%) 16 (27%) 0 ACE inhibitor 41 (38%) 16 (38%) 23 (39%) 2 (33%) ARB 8 (7%) 3 (7%) 4 (7%) 1 (17%) ACE, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers. Other pacing indication includes those with atrial tachyarrhythmias, chronic bifascicular and trifascicular block, hypersensitive carotid sinus syndrome or vasovagal syncope. Table 2 Percent ventricular pacing in MVP mode, by primary pacing indication Primary pacing indication n Median Cum%VP Total SND AVB Other AVB was 50.3% (11.6% in patients with episodic third degree AVB and 99.4% in patients with persistent third degree AVB). Cum%VP 40% Figure 2 shows the results for the Cum%VP 40% objective. A Cum%VP 40% was noticed in 72% of all 107 patients, in 86% of 59 SND patients, and in 50% of 42 AVB patients. At the PHD visit, an AV conduction test was performed. A Cum%VP 40% was noticed in 92% of 65 patients with 1:1 AV conduction at PHD and in 24% of 17 patients without AV conduction at PHD. Overall, 61% of patients had Cum%VP, 10%, while 54% of patients had Cum%VP 5%, and 40% had Cum%VP 1%. Adverse events No adverse events related to MVP were reported during the entire follow-up period of 76.3 days with a range of days. No patient died and no unanticipated serious adverse device effect occurred. Discussion In this study, we found that the median Cum%VP in unselected, consecutively enrolled patients with a conventional dual chamber pacemaker indication 9 programmed to MVP mode at the 1-month post implant visit was 3.9%. In 54% of patients, Cum%VP was as low as 5%, and in 40% further diminished to 1%. In addition, 72% of patients achieved a Cum%VP 40%. Our results are in line with the recently published studies by Sweeney et al. 7,10 and Gillis et al. 8, who showed a substantial reduction in percent ventricular pacing using the MVP mode, compared to the DDD/R mode. We observed that a low median Cum%VP can even be achieved in patients with AVB (8.6% and 6.6% in first and second degree AVB, respectively). The MOST study 4 showed that Cum%VP more than 40% of time was the cut point which significantly increased the risk of heart failure hospitalization. When ventricular pacing in DDD/R mode was 40%, for each 10% increase in ventricular pacing there was a 54% relative increase in risk for heart failure hospitalization, and when ventricular pacing was greater than 40% a patient s relative risk for heart failure hospitalization remained elevated and constant. Therefore, in the present study, we focused on assessing for which patients in a standard bradycardia population it would be possible to achieve Cum%VP 40%. Our results showed that Cum%VP 40% occurred in 72% of all patients and in 86% of patients with SND. Our study shows that even in 50% of patients with AVB, it is possible to achieve Cum%VP 40%. In addition, the MOST study also showed that the lowest rate of heart failure hospitalization occurred in patients who were paced, 10% of time. 4 In our study, 61% of patients are paced, 10% in the MVP mode. Although these results suggest a beneficial prognosis for these patients, the clinical benefit of this effect of MVP needs to be proven and evaluated in a randomized outcome study. Although a very low percent Cum%VP can be achieved in patients with SND as primary pacing indication, 14% of these patients show Cum%VP more than 40% of time.
4 154 G. Milasinovic et al. Figure 1 Distribution of Cum%VP and Cum%AP in sinus node disease and AV block patients. Table 3 patients Percent ventricular pacing in MVP mode in AV block AVB status n a Median Cum%VP First degree AVB Second degree AVB Third degree AVB Episodic Persistent AVB status was derived from the Medical History of patients. a Not mutually exclusive. A possible explanation could be that these patients have intermittent AV block as well, which prevents reaching a low percent ventricular pacing in these patients. Similar observations were seen in the study by Sweeney et al., 7 where MVP mode in SND patients with intermittent or persistent AVB resulted in switches to DDD/R mode. The study showed that programming the mean PAV/SAV delay to 243/ 219 ms during DDD/R operation did not prevent ventricular pacing. Another reason which stresses the importance of eliminating ventricular pacing as much as possible is that a recent study showed that bradycardia pacing might facilitate short long short cycle lengths, which might initiate ventricular tachycardia (VT) and ventricular fibrillation (VF). 11 Although the study showed that this pacing facilitated onset of VT/VF episodes occurs in all pacing modes (DDD/ R, VVI/R, MVP), the occurrence in patients programmed to MVP was the lowest. In the presence of hypokalemia or long QT syndrome, pause permitting pacemaker features in DDD/R or MVP have been associated with symptoms 12 or Torsades des Pointes. 13,14 In these patients, careful consideration should be given to pacemaker mode and lower rate programming. Figure 2 No patients experienced Torsades des Pointes or symptoms due to non-physiologic AV intervals in this study. Limitations Percentage of patients with Cum%VP 40%. We only studied the effect of MVP on the burden of ventricular pacing. Clinical benefit and the effects of reduced ventricular pacing on symptoms and haemodynamics were not studied. However, it was recently shown that dual-chamber minimal ventricular pacing, when compared with conventional dual-chamber pacing, reduces the absolute risk of persistent atrial fibrillation by 4.8% in patients with SND. 15 A second limitation of our study is that we only investigated the effect on percent of ventricular pacing over a period of 1-month. Therefore, no conclusion can be drawn for the longer term, although Gillis et al. 8 showed that the reduced percent ventricular pacing during MVP was sustained over longer term follow-up. Furthermore, it is difficult to relate the observed percent AP to MVP, since the atrial-overdrive feature APP was required to be programmed ON in Phase I patients with a history of atrial arrhythmias. This resulted in APP being
5 Percent ventricular pacing with MVP mode 155 ON in 62% of Phase I patients, and in 30% of Phase II patients (in Phase II, this decision was up to the physicians discretion). Finally, the Adapta IPG is based on the FDA approved Kappa w and EnPulse w devices, and the new features are either functionally equivalent to those in already regulatory-body-approved products (MVP and Atrial Preference Pacing), or do not represent a safety hazard (Therapy- Guide and Rate Response User Interface). Therefore, to evaluate the safety and performance of the Adapta IPG, a control group (e.g. DDD/R) was not needed. For this reason, in this study, we can only report descriptive values of percent ventricular pacing, and no reduction can be demonstrated. However, the reported low values of percent ventricular pacing with MVP in our population are in line with previous studies. 7,8 Conclusion In conclusion, the MVP mode is able to achieve a low percent of ventricular pacing in a standard pacemaker population consisting of SND and AVB patients. In addition, MVP resulted in a Cum%VP 40% in 72% of patients after 1-month. Clinical benefits of these effects need to be investigated. Acknowledgements The authors thank John M. Morgan, MD, for his critical review of the manuscript. Conflict of interest. This study was sponsored by Medtronic Inc. All authors were participants/investigators in this study. J.B. received honoraria from Medtronic, St Jude Medical, Biotronik, and Boston Scientific for speaking engagements; C.W. is a Statistician for and holds stock in Medtronic; M.H. is a Clinical Research Specialist for Medtronic. Funding Medtronic, Inc. was the sponsor of this study. References 1. Tse HF, Lau CP. Long-term effect of right ventricular pacing on myocardial perfusion and function. J Am Coll Cardiol 1997;29: Tse HF, Yu C, Wong KK, Tsang V, Leung YL, Ho WY. Functional abnormalities in patients with permanent right ventricular pacing. J Am Coll Cardiol 2002;40: Nielsen JC, Kristensen L, Andersen HR, Mortensen PT, Pedersen O, Pedersen AK. A randomized comparison of atrial and dual-chamber pacing in 177 consecutive patients with sick sinus syndrome: echocardiographic and clinical outcome. J Am Coll Cardiol 2003;42: Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee KL et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 2003;23: Wilkoff BL, Cook JR, Epstein AE, Green HL, Hallstrom AP, Hsia H et al. The DAVID Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002; 288: Sharma AD, Rizo-Patron C, Hallstrom AP, O Neill GP, Rothbart S, Martins JB et al. Percent right ventricular pacing predicts outcomes in the DAVID trial. Heart Rhythm 2005;2: Sweeney MO, Ellenbogen KA, Casavant D, Betzold R, Sheldon T, Tang F et al. Multicenter, prospective, randomized safety and efficacy study of new atrial-based managed ventricular pacing mode (MVP) in dualchamber ICDs. J Cardiovasc Electrophysiol 2005;16: Gillis AM, Pürerfellner H, Israel CW, Sunthorn H, Kacet S, Anelli-Monti M et al. Reducing unnecessary right ventricular pacing with the managed ventricular pacing mode in patients with sinus node disease and AV block. PACE 2006;29: Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA et al. ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 2002;106: Sweeney MO, Shea JB, Fox V, Adler S, Nelson L, Mullen TJ et al. Randomized pilot study of a new atrial-based minimal ventricular pacing mode in dual-chamber implantable cardioverter-defibrillators. Heart Rhythm 2004;1: Sweeney MO, Ruetz LL, Belk P, Mullen TJ, Johnson JW, Sheldon T. Bradycardia pacing induced short long short sequences at the onset of ventricular tachyarrhythmias: a possible mechanism of proarrhythmia? JAm Coll Cardiol 2007;50: Mansour F, Talajic M, Thibault B, Khairy P. Pacemaker troubleshooting: when MVP is not the most valuable parameter. Heart Rhythm 2006;3: Pinski SL, Eguia L, Trohman RG. What is the minimal pacing rate that prevents Torsades de Pointes? Insights from patients with permanent pacemakers. Pacing Clin Electrophysiol 2002;25: Van Mechelen R. Schoonderwoerd. Risk of managed ventricular pacing in a patient with heart block. Heart Rhythm 2006;3: Sweeney MO, Bank AJ, Nsah E, Koullick M, Zeng QC, Hettrick D et al. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. N Engl J Med 2007;357:
PACING SYSTEMS.
References 1 Ensura SR MRI SureScan EN1SR01 Clinician Manual. 2 Medtronic Adapta ADSR01/03/06 Implant Manual, 2005. 3 Advisa MRI SureScan pacing system included on the ARTG 22/8/2009, with full body MRI
More informationIntroduction. CLINICAL RESEARCH Pacing and CRT
Europace (2010) 12, 96 102 doi:10.1093/europace/eup252 CLINICAL RESEARCH Pacing and CRT Difference in percentage of ventricular pacing between two algorithms for minimizing ventricular pacing: results
More informationHow to prevent unecessary right ventricular pacing
How to prevent unecessary right ventricular pacing Jens Cosedis Nielsen, MD, PhD, DMSci Dept of Cardiology, Aarhus University Hospital, Skejby, Denmark June 27, 2011, Europace Madrid Conflicts of interest
More informationIntroduction. CLINICAL RESEARCH Pacing and resynchronization therapy. Hermine R. Poghosyan* and Smbat V. Jamalyan. Aims
Europace (2012) 14, 1483 1489 doi:10.1093/europace/eur415 CLINICAL RESEARCH Pacing and resynchronization therapy Comparison of pacing algorithms to avoid unnecessary ventricular pacing in patients with
More informationProgramming of Bradycardic Parameters. C. W. Israel, M.D. Dept. of Cardiology Evangelical Hospital Bielefeld Germany
Programming of Bradycardic Parameters C. W. Israel, M.D. Dept. of Cardiology Evangelical Hospital Bielefeld Germany Carsten.Israel@evkb.de Programming of ICD Brady Parameters Conflict of Interest Biotronik
More informationDipartimento di Scienze Cardiovascolari Università Campus Bio-Medico di Roma Dott. Vito Calabrese
Dipartimento di Scienze Cardiovascolari Università Campus Bio-Medico di Roma Dott. Vito Calabrese Because the primary objective was cure symptomatic bradicardya due to syncope Because this is the common
More informationWide QRS Tachycardia in a Dual Chamber Pacemaker Patient: What is the Mechanism?
CASE REPORTS Arrhythmia 2015;16(3):173-177 doi: http://dx.doi.org/10.18501/arrhythmia.2015.029 Wide QRS Tachycardia in a Dual Chamber Pacemaker Patient: What is the Mechanism? Eun-Sun Jin, MD, PhD Cardiovascular
More informationAn Overview of Cardiac Pacing in Jamaica. Part II: Indications, Modes and Arrhythmia Prevalence R Irvine 1, A Coy 2, M Voutchkov 2 ABSTRACT
An Overview of Cardiac Pacing in Jamaica. Part II: Indications, Modes and Arrhythmia Prevalence R Irvine 1, A Coy 2, M Voutchkov 2 ABSTRACT Objective: To present a report of the indications for cardiac
More informationCLINICAL SUMMARY COGENT-4 FIELD FOLLOWING STUDY
CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician trained or experienced in device implant and follow-up procedures. CLINICAL SUMMARY COGENT-4 FIELD FOLLOWING STUDY
More informationBradycardia Pacing-Induced Short-Long-Short Sequences at the Onset of Ventricular Tachyarrhythmias
Journal of the American College of Cardiology Vol., No., by the American College of Cardiology Foundation ISSN -//$. Published by Elsevier Inc. doi:./j.jacc... Heart Rhythm Disorders Bradycardia -Induced
More informationShock Reduction Strategies Michael Geist E. Wolfson MC
Shock Reduction Strategies Michael Geist E. Wolfson MC Shock Therapy Thanks, I needed that! Why Do We Need To Reduce Shocks Long-term outcome after ICD and CRT implantation and influence of remote device
More informationDoes Reducing Unnecessary Right Ventricular Pacing Improve Sympathetic Activity and Innervation of Heart in Sinus Node Disease Patients?
Does Reducing Unnecessary Right Ventricular Pacing Improve Sympathetic Activity and Innervation of Heart in Sinus Node Disease Patients? MVP and SafeR Study Mihoko Miyamoto, 1 MD, Yuichiro Kimura, 1 MD,
More informationPrimary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life
Chapter 3 Primary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life Guido H. van Welsenes, MS, Johannes B. van Rees, MD, Joep Thijssen, MD, Serge
More informationEHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs
EHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs Dear EHRA Member, Dear Colleague, As you know, the EHRA Accreditation Process is becoming increasingly recognised as an important step for
More informationFriedman, Rott, Wokhlu, Asirvatham, Hayes 201. Figure 65.7 Shortening of the AV interval during pacing.
Friedman, Rott, Wokhlu, Asirvatham, Hayes 201 Figure.7 Shortening of the AV interval during pacing. 202 A Case-Based Approach to Pacemakers, ICDs, and Cardiac Resynchronization Figure.8 is obtained from
More informationAutomatic assessment of atrial pacing threshold in current medical practice
Europace (212) 14, 1615 1619 doi:1.193/europace/eus76 CLINICAL RESEARCH Leads and lead extraction Automatic assessment of atrial pacing threshold in current medical practice Jean Luc Rey 1, Serge Quenum
More informationTreatment of AF by Pacing Therapy Is there Anything Else Beyond AVN Ablation?
1 Treatment of AF by Pacing Therapy Is there Anything Else Beyond AVN Ablation? Chu-Pak Lau, MD Honorary Clinical Professor Queen Mary Hospital The University of Hong Kong How to Prevent AF by Pacing 1.
More informationPARAD/PARAD+ : P and R Based Arrhythmia Detection
Tech Corner PARAD/PARAD+ : P and R Based Arrhythmia Detection NOTE: PLEASE NOTE THAT THE FOLLOWING INFORMATION IS A GENERAL DESCRIPTION OF THE FUNCTION. DETAILS AND PARTICULAR CASES ARE NOT DESCRIBED IN
More informationEffect of Ventricular Pacing on Myocardial Function. Inha University Hospital Sung-Hee Shin
Effect of Ventricular Pacing on Myocardial Function Inha University Hospital Sung-Hee Shin Contents 1. The effect of right ventricular apical pacing 2. Strategies for physiologically optimal ventricular
More informationI n patients with sick sinus syndrome (SSS), normal
661 CARDIOVASCULAR MEDICINE Incidence of atrial fibrillation and thromboembolism in a randomised trial of atrial versus dual chamber pacing in 177 patients with sick sinus syndrome L Kristensen, J C Nielsen,
More informationGöran Kennebäck 1 *, Fariborz Tabrizi 1,2, Peter Lindell 1, and Rolf Nordlander 2. Introduction. Methods. Patient population
Europace (2007) 9, 186 191 doi:10.1093/europace/eul185 High-degree atrioventricular block during anti-arrhythmic drug treatment: use of a pacemaker with a bradycardia-detection algorithm to study the time
More informationMinimizing Ventricular Pacing to Reduce Atrial Fibrillation in Sinus-Node Disease
T h e n e w e ng l a nd j o u r na l o f m e dic i n e original article Minimizing Ventricular Pacing to Reduce Atrial Fibrillation in Sinus-de Disease Michael O. Sweeney, M.D., Alan J. Bank, M.D., Emmanuel
More informationNational Coverage Determination (NCD) for Cardiac Pacemakers (20.8)
Page 1 of 12 Centers for Medicare & Medicaid Services National Coverage Determination (NCD) for Cardiac Pacemakers (20.8) Tracking Information Publication Number 100-3 Manual Section Number 20.8 Manual
More informationImpact of atrial antitachycardia pacing and atrial pace prevention therapies on atrial fibrillation burden over long-term follow-up
Europace (2009) 11, 1041 1047 doi:10.1093/europace/eup115 CLINICAL RESEARCH Pacing and CRT Impact of atrial antitachycardia pacing and atrial pace prevention therapies on atrial fibrillation burden over
More informationContinuous ECG telemonitoring with implantable devices: the expected clinical benefits
Continuous ECG telemonitoring with implantable devices: the expected clinical benefits C. W. Israel, M.D. Dept. of Cardiology Evangelical Hospital Bielefeld Germany Carsten.Israel@evkb.de Declaration of
More informationClinical Results with the Dual-Chamber Cardioverter Defibrillator Phylax AV - Efficacy of the SMART I Discrimination Algorithm
April 2000 107 Clinical Results with the Dual-Chamber Cardioverter Defibrillator Phylax AV - Efficacy of the SMART I Discrimination Algorithm B. MERKELY Semmelweis University, Dept. of Cardiovascular Surgery,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA88; Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block
More informationPacing Codes and Modes Concepts
Pacing Codes and Modes Concepts Pacing codes and modes concepts Objectives Upon completion of this program the participant will be able to: State what the first four positions of the NBG code represent.
More informationRecurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm
Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm Guy Amit, MD, MPH Soroka University Medical Center Ben-Gurion University of the Negev Beer-Sheva, Israel Disclosures Consultant:
More informationIntroduction. CLINICAL RESEARCH Pacing and CRT
Europace (2010) 12, 202 209 doi:10.1093/europace/eup346 CLINICAL RESEARCH Pacing and CRT Trend of the main clinical characteristics and pacing modality in patients treated by pacemaker: data from the Italian
More informationSummary, conclusions and future perspectives
Summary, conclusions and future perspectives Summary The general introduction (Chapter 1) of this thesis describes aspects of sudden cardiac death (SCD), ventricular arrhythmias, substrates for ventricular
More informationMEDTRONIC CARELINK NETWORK FOR PACEMAKERS. Comparison between the Medtronic CareLink Network for Pacemakers and Transtelephonic Monitoring
MEDTRONIC CARELINK NETWORK FOR PACEMAKERS Comparison between the Medtronic CareLink Network for Pacemakers and Transtelephonic Monitoring Transtelephonic Monitoring Transmission What can you determine
More informationCardiac Resynchronisation Therapy for all Patients Requiring Ventricular Pacing
Cardiac Resynchronisation Therapy for all Patients Requiring Ventricular Pacing Philippe Mabo University Hospital, Rennes, France ESC Congress 2010, Stockholm 29 Aug 2010 Which Patients? Candidate for
More informationIntroduction. CLINICAL RESEARCH Clinical Trial Design. Mohammad Saeed 1 *, Mehdi Razavi 1, Curtis G. Neason 2, and Simona Petrutiu 2. Aims.
Europace (2011) 13, 1648 1652 doi:10.1093/europace/eur195 CLINICAL RESEARCH Clinical Trial Design Rationale and design for programming implantable cardioverter defibrillators in patients with primary prevention
More informationCardiac Rhythm Device Management. PBL STOP Your acronym for a standardized follow-up
Cardiac Rhythm Device Management PBL STOP Your acronym for a standardized follow-up What s in it for you? What do you need to feel comfortable with a pacemaker/icd follow-up? 2 CORE OBJECTIVE Provide a
More informationBHRS Prep course Pub style Quiz NOT A
BHRS Prep course Pub style Quiz NOT A Round 1 Quiz questions Common ECG s in CRM Colin Cunnington Over the past 3 months, a 24-yearold man who works as a truck driver has had frequent episodes of pre-syncope
More informationEvolution of pacemaker technology has resulted in the
Relationship Between Pacemaker Dependency and the Effect of Pacing Mode on Cardiovascular Outcomes Anthony S.L. Tang, MD; Robin S. Roberts, MTech; Charles Kerr, MD; Anne M. Gillis, MD; Martin S. Green,
More informationNew generations pacemakers and ICDs: an update
Advances in Cardiac Arrhythmias and Great Innovations in Cardiology XXVII Giornate Cardiologiche Torinesi New generations pacemakers and ICDs: an update Prof. Fiorenzo Gaita, MD Division of Cardiology
More informationComparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure
HOT TOPIC Cardiology Journal 2010, Vol. 17, No. 6, pp. 543 548 Copyright 2010 Via Medica ISSN 1897 5593 Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart
More informationPATIENT WITH ARRHYTHMIA IN DENTIST S OFFICE. Małgorzata Kurpesa, MD., PhD. Chair&Department of Cardiology
PATIENT WITH ARRHYTHMIA IN DENTIST S OFFICE Małgorzata Kurpesa, MD., PhD. Chair&Department of Cardiology Medical University of Łódź The heart is made up of four chambers Left Atrium Right Atrium Left Ventricle
More informationThe Role of Pacemakers in the Management of Patients with Atrial Fibrillation
The Role of Pacemakers in the Management of Patients with Atrial Fibrillation Gautham Kalahasty, MD a, *, Kenneth Ellenbogen, MD a,b KEYWORDS Pacemaker Implantable cardioverter defibrillator Atrial fibrillation
More informationInteractive Simulator for Evaluating the Detection Algorithms of Implantable Defibrillators
22 March 2002 Interactive Simulator for Evaluating the Detection Algorithms of Implantable Defibrillators F. HINTRINGER, O. PACHINGER Division of Cardiology, Department for Internal Medicine, University
More informationEvera MRI S SureScan FIRST. Fit for LIVING. Fit for MRI. ICD SYSTEM
Evera MRI S SureScan ICD SYSTEM Fit for LIVING. Fit for MRI. FULL BODY FIRST MRI ICD It s contoured. 3 reduction in skin pressure, designed for greater patient comfort. 1 It lasts longer. Up to 25% greater
More informationNeed to Know: Implantable Devices. Carolyn Brown RN, MN, CCRN Education Coordinator Emory Healthcare Atlanta, Georgia
Need to Know: Implantable Devices Carolyn Brown RN, MN, CCRN Education Coordinator Emory Healthcare Atlanta, Georgia Disclosure Statement I have no relationships to disclose. Objectives Discuss the most
More informationENGINEERED TO ENABLE THE FUTURE OF CONNECTED HEALTH
ENGINEERED TO ENABLE THE FUTURE OF CONNECTED HEALTH Introducing Azure with BlueSync Technology Completely Redesigned Improved Longevity 1 AF Detection and Reduction 2 Secure Wireless Communication with
More informationCONTAK RENEWAL CLINICAL SUMMARY
CAUTION: Federal law restricts this device to sale by or on the order of a physician trained or experienced in device implant and follow-up procedures. CLINICAL SUMMARY CONTAK RENEWAL Boston Scientific
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review
More informationDevice Interrogation- Pacemakers, ICD and Loop Recorders. Dulce Obias-Manno, RN, MHSA, CCDS,CEPS, FHRS Device Clinic Coordinator, MHVI
Device Interrogation- Pacemakers, ICD and Loop Recorders Dulce Obias-Manno, RN, MHSA, CCDS,CEPS, FHRS Device Clinic Coordinator, MHVI Disclosures Consultant: Medtronic Speaker s Bureau: St. Jude Medical
More informationTeaching Rounds in Cardiac Electrophysiology
Teaching Rounds in Cardiac Electrophysiology Sustained Multiple Railroad Tracks on Implantable Cardiac Defibrillator Interval Plots Mechanisms and Management Alex Y. Tan, MD; Kenneth A. Ellenbogen, MD;
More informationEvera MRI XT SureScan ICD SYSTEM
References 1 Flo, Daniel. Device Shape Analysis. January 2013. Medtronic data on file. 2 Evera MRI DR/VR ICD Manuals. Protecta DR/VR ICD Manuals. 3 Schloss EJ, Auricchio A, Kurita T, et al. PainFree SST
More informationRight Ventricular Pacing: The Evidence and
Right Ventricular Pacing: The Evidence and Ways to Optimize i for Patients t Melanie T. Gura, RN, MSN, CNS, CCDS, FHRS, FAHA Director, Pacemaker & Arrhythmia Services Northeast Ohio Cardiovascular Specialists
More informationImplications of mechanism of bradycardia on response to pacing in patients with unexplained syncope
Europace (2007) 9, 312 318 doi:10.1093/europace/eum020 Implications of mechanism of bradycardia on response to pacing in patients with unexplained syncope Sachin Sud, George J. Klein, Allan C. Skanes,
More informationDevice based CRT optimization: is there a future? Lessons learned from published trials
Device based CRT optimization: is there a future? Lessons learned from published trials C. Leclercq Department of Cardiology Centre Cardio-Pneumologique Rennes, France Presenter Disclosure Information
More informationESC/EHRA. Guidelines on Cardiac Pacing. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece
ESC/EHRA Guidelines on Cardiac Pacing Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Reasons for European Guidelines? Scientific reasons Cultural and political reasons
More informationCarlo Budano. Closed loop physiological stimulation: from the pacemaker patient to the patient with an ICD
Closed loop physiological stimulation: from the pacemaker patient to the patient with an ICD Carlo Budano Dipartimento Cardiovascolare Città della Salute e della Scienza di Torino Physiological rate regulation
More informationAutomatic Atrial Threshold Measurement and Adjustment in Pediatric Patients
Automatic Atrial Threshold Measurement and Adjustment in Pediatric Patients ANITA HIIPPALA, M.D.,* GERALD A. SERWER, M.D., EVA CLAUSSON, M.Sc., LYNN DAVENPORT, M.S., TRINA BRAND, PH.D., and JUHA-MATTI
More informationCost Advantage of Dual-Chamber Versus Single-Chamber Cardioverter-Defibrillator Implantation
Journal of the American College of Cardiology Vol. 46, No. 5, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.061
More informationEpidemiological data from the Framingham heart study indicate that the cumulative incidence
106 * Electrophysiology PACING FOR ATRIAL FIBRILLATION c PHARMACOTHERAPY Correspondence to: Professor Chu-Pak Lau, Cardiology Division, University of Hong Kong, Queen Mary Hospital, Hong Kong; cplau@hkucc.hku.hk
More informationCardiac Implanted Electronic Devices Pacemakers, Defibrillators, Cardiac Resynchronization Devices, Loop Recorders, etc.
Cardiac Implanted Electronic Devices Pacemakers, Defibrillators, Cardiac Resynchronization Devices, Loop Recorders, etc. The Miracle of Living February 21, 2018 Matthew Ostrom MD,FACC,FHRS Division of
More informationThe effect of cardiac pacemaker implantation on cardiac performance the experience of a Cardiology Rehabilitation Department
The effect of cardiac pacemaker implantation on cardiac performance the experience of a Cardiology Rehabilitation Department Coresponding author: Dana Pop E-mail address: pop67dana@gmail.com Bogdan Caloian
More informationRole of the AV Interval in DDD Pacing: Insights into Programming with Respect to Ventricular Function when AV Nodal Conduction is Intact
Role of the AV Interval in DDD Pacing: Insights into Programming with Respect to Ventricular Function when AV Nodal Conduction is Intact Paul A. Levine, MD, FHRS, FACC Vice President, Medical Services,
More informationIs This Thing Working?
Is This *#@!* Thing Working? Pacemaker (and ICD) ECG and Telemetry Pitfalls Wayne O. Adkisson, MD adki0004@umn.edu Disclosures I currently receive research support from Medtronic, Inc. I have been compensated
More informationCONSULTA CRT-P Model C4TR01
CONSULTA CRT-P Model C4TR01 Physical characteristics Volume a 15 cm 3 Mass H x W x D Surface area of titanium device can Surface area of each titanium nitride LECG electrode Radiopaque ID Materials in
More informationAnalyses of risk factors and prognosis for new-onset atrial fibrillation in elderly patients after dual-chamber pacemaker implantation
Journal of Geriatric Cardiology (2018) 15: 628 633 2018 JGC All rights reserved; www.jgc301.com Research Article Open Access Analyses of risk factors and prognosis for new-onset atrial fibrillation in
More informationIntermittent episodes of paced tachycardia: what is the cause?
Intermittent episodes of paced tachycardia: what is the cause? Lindsey Parkinson and Lucy Broadhurst, Rotherham NHS Foundation Trust Contact: Lindsey.Parkinson@rothgen.nhs.uk Introduction A hospital in-patient
More informationG Lin, R F Rea, S C Hammill, D L Hayes, P A Brady
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA Correspondence to: Dr Peter A Brady, MD, FRCP, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA; brady.peter@mayo.edu Accepted
More informationDecember D. EL ALLAF Centre Hospitalier Hutois, Huy, Belgium. P. ATTUEL Centre Chirurgical Val d'or, Saint Cloud, France
December 2000 449 European Multicenter Study on the Prevention of Paroxysmal Atrial Fibrillation by Permanent Overdrive Pacing: Atrial Rate Behavior and Patient Tolerance D. EL ALLAF Centre Hospitalier
More informationJournal of Arrhythmia
Journal of Arrhythmia 29 (2013) 204 210 Contents lists available at ScienceDirect Journal of Arrhythmia journal homepage: www.elsevier.com/locate/joa Original Article Factors involved in correct analysis
More informationUse of a new cardiac pacing mode designed to eliminate unnecessary ventricular pacing
Europace (2006) 8, 96 101 doi:10.1093/europace/euj024 Use of a new cardiac pacing mode designed to eliminate unnecessary ventricular pacing Gerd Fröhlig 1 *, Daniel Gras 2, Jacques Victor 3, Philippe Mabo
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationThe effect of anti-tachycardia atrial pacing in patients with recurrent paroxysmal atrial fibrillation
ORIGINAL ARTICLE Folia Cardiol. 2006, Vol. 13, No. 7, pp. 590 595 Copyright 2006 Via Medica ISSN 1507 4145 The effect of anti-tachycardia atrial pacing in patients with recurrent paroxysmal atrial fibrillation
More informationThe Management of Heart Failure after Biventricular Pacing
The Management of Heart Failure after Biventricular Pacing Juan M. Aranda, Jr., MD University of Florida College of Medicine, Division of Cardiovascular Medicine, Gainesville, Florida Approximately 271,000
More informationESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309
ESC Guidelines Update 2008 ESC Guidelines Heart failure update 2008 For internal training purpose. 0 Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC
More informationDevice Diagnostics and Stroke Prevention: State of the Art
Device Diagnostics and Stroke Prevention: State of the Art Ass. Prof. Dr. Carsten W. Israel Dept. of Cardiology Evangelical Hospital Bielefeld Germany C.W.Israel@em.uni-frankfurt.de Disclosure of Relationships
More informationTech Corner. ATP in the Fast VT zone
Tech Corner ATP in the Fast VT zone NOTE: PLEASE NOTE THAT THE FOLLOWING INFORMATION IS A GENERAL DESCRIPTION OF THE FUNCTION. DETAILS AND PARTICULAR CASES ARE NOT DESCRIBED IN THE ARTICLE. FOR ADDITIONAL
More informationPreventive Pacing in Atrial Fibrillation
358 September 2001 Preventive Pacing in Atrial Fibrillation W. KAINZ Department of Cardiology, Hanusch Hospital, Vienna, Austria Summary Patients with paroxysmal atrial fibrillation are often highly symptomatic,
More informationDialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
More informationMANAGEMENT OF ASYMPTOMATIC BRADYCARDIA. Pr. HABIB HAOUALA Service de Cardiologie Hôpital militaire de Tunis
MANAGEMENT OF ASYMPTOMATIC BRADYCARDIA Pr. HABIB HAOUALA Service de Cardiologie Hôpital militaire de Tunis DISCLOSURE STATEMENT OF FINANCIAL INTEREST Grant/research: Medtronic;Sanofi; Novartis Consulting
More informationIMPLANTABLE CARDIODEFIBRILLATORS (ICDS)
IMPLANTABLE CARDIODEFIBRILLATORS (ICDS) Protocol: CAR024 Effective Date: June 1, 2018 Table of Contents Page DESCRIPTION... 1 COMMERCIAL & MEDICAID COVERAGE RATIONALE... 1 MEDICARE COVERAGE RATIONALE...
More informationCritical Analysis of Dual-Chamber Implantable Cardioverter-Defibrillator Arrhythmia Detection
Critical Analysis of Dual-Chamber Implantable Cardioverter-Defibrillator Arrhythmia Detection Results and Technical Considerations Bruce L. Wilkoff, MD; Volker Kühlkamp, MD; Kent Volosin, MD; Kenneth Ellenbogen,
More informationDual chamber pacing mode in an atrial antitachycardia pacing device without a ventricular lead e A necessary evil
indian pacing and electrophysiology journal 15 (2015) 133e137 HOSTED BY Available online at www.sciencedirect.com ScienceDirect journal homepage: www.elsevier.com/locate/ipej Dual chamber pacing mode in
More informationModelling the health benefits and economic implications of implanting dual-chamber vs. single-chamber ventricular pacemakers in the UK
Europace (2006) 8, 449 455 doi:10.1093/europace/eul042 Modelling the health benefits and economic implications of implanting dual-chamber vs. single-chamber ventricular pacemakers in the UK Jaime Caro
More informationTemporary pacemaker 삼성서울병원 심장혈관센터심장검사실 박정왜 RN, CCDS
Temporary pacemaker 삼성서울병원 심장혈관센터심장검사실 박정왜 RN, CCDS NBG Codes 1st Letter 2nd Letter 3rd Letter A V D Chamber(s) Paced = atrium = ventricle = dual (both atrium and ventricle) Chamber(s) Sensed A = atrium
More informationOHTAC Recommendation: Internet- Based Device-Assisted Remote Monitoring of Cardiovascular Implantable Electronic Devices
OHTAC Recommendation: Internet- Based Device-Assisted Remote Monitoring of Cardiovascular Implantable Electronic Devices Ontario Health Technology Advisory Committee January 2012 Issue Background The Ontario
More information11/21/18. EKG Pop Quiz. Michael Giocondo, MD Cardiac Electrophysiology Saint Luke s Cardiovascular Consultants
EKG Pop Quiz Michael Giocondo, MD Cardiac Electrophysiology Saint Luke s Cardiovascular Consultants 1 Disclosures No financial relationships to disclose. EKG #1 75 y/o woman with a dual-chamber pacemaker
More informationBrian Olshansky, MD, FHRS,* John D. Day, MD, FHRS, Renee M. Sullivan, MD,* Patrick Yong, MSEE, Elizabeth Galle, MS, Jonathan S. Steinberg, MD, FHRS
Does cardiac resynchronization therapy provide unrecognized benefit in patients with prolonged PR intervals? The impact of restoring atrioventricular synchrony: An analysis from the COMPANION Trial Brian
More informationPACEMAKER INTERPRETATION AND DEVICE MANAGEMENT PART I
1 PACEMAKER INTERPRETATION AND DEVICE MANAGEMENT PART I Cynthia Webner DNP, RN, CCNS, CCRN-CMC Karen Marzlin DNP, RN, CCNS, CCRN-CMC 2 PROFESSIONAL NURSING PRACTICE CAN ONLY ADVANCE AS MUCH AS INDIVIDUAL
More informationEBR Systems, Inc. 686 W. Maude Ave., Suite 102 Sunnyvale, CA USA
Over 200,000 patients worldwide are estimated to receive a CRT device each year. However, limitations prevent some patients from benefiting. CHALLENGING PROCEDURE 5% implanted patients fail to have coronary
More informationCurrent guidelines for device-based therapy of cardiac
Long-Term Benefit of Primary Prevention With an Implantable Cardioverter-Defibrillator An Extended 8-Year Follow-Up Study of the Multicenter Automatic Defibrillator Implantation Trial II Ilan Goldenberg,
More informationBIVENTRICULAR PACEMAKER (CARDIAC RESYNCHRONIZATION THERAPY) FOR THE TREATMENT OF HEART FAILURE
FOR THE TREATMENT OF HEART FAILURE Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationCardiac Pacemakers» 2013 HOSPITAL REIMBURSEMENT GUIDE
Cardiac Pacemakers» 2013 HOSPITAL REIMBURSEMENT GUIDE 2 Contents Page Introduction Medicare Coding and Payment Overview Hospital Inpatient Hospital Outpatient HCPCS Device Category C-Codes Coverage for
More informationCardiac rhythm detailed monitoring by an implanted pacemaker: The iecg solution
Cardiac rhythm detailed monitoring by an implanted pacemaker: The iecg solution Francesco Zanon, MD, FESC, FHRS Arrhythmia and Electrophysiology Unit, Cardiology Dept. Santa Maria della Misericordia General
More informationJournal of Arrhythmia
Journal of Arrhythmia 28 (2012) 91 95 Contents lists available at SciVerse ScienceDirect Journal of Arrhythmia journal homepage: www.elsevier.com/locate/joa Review Unresolved matters related to implantable
More informationConventional and biventricular pacing in patients with first-degree atrioventricular block
Europace (2012) 14, 1414 1419 doi:10.1093/europace/eus089 REVIEW Conventional and biventricular pacing in patients with first-degree atrioventricular block S. Serge Barold* and Bengt Herweg Florida Heart
More informationDual-Chamber Implantable Cardioverter-Defibrillator
February 1998 9 Dual-Chamber Implantable Cardioverter-Defibrillator A.SH. REVISHVILI A.N. Bakoulev Research Center for Cardiovascular Surgery, Russian Academy of Medical Sciences, Moscow, Russia Summary
More informationChapter 2. Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients
Chapter 2 Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients Guido H. van Welsenes, MS, Johannes B. van Rees, MD, C. Jan Willem Borleffs, MD, PhD, Suzanne
More informationAmbulatory Monitors, Pacers, and Defibrillators
Ambulatory Monitors, Pacers, and Defibrillators Vermont Cardiac Network 2018 Mark L. Greenberg MD Clinical Associate Professor of Medicine Geisel School of Medicine, Dartmouth Mark.L.Greenberg@Dartmouth.edu
More informationENABLE MRI CLINICAL STUDY SUMMARY
CLINICAL STUDY SUMMARY ENABLE MRI CAUTION: Federal Law restricts this device to sale by or on the order of a physician trained or experienced in device implant and follow-up procedures. TABLE OF CONTENTS
More informationHeart Rate Variability Analysis Before and After Pacemaker Implantation in Neuromediated Syncopal Patients
148 April 2001 Heart Rate Variability Analysis Before and After Pacemaker Implantation in Neuromediated Syncopal Patients F. ZOLEZZI, C. ORVIENI, R. NEGRO, C.A. MAZZINI Division of Cardiology, Ospedale
More informationNational Horizon Scanning Centre. Dronedarone (Multaq) for atrial fibrillation and atrial flutter. December 2007
Dronedarone (Multaq) for atrial fibrillation and atrial flutter December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More information